Publications by authors named "C Larbouret"
Article Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) shows treatment resistance due to a dense stroma and immunosuppressive microenvironment, prompting research into combining FOLFIRINOX chemotherapy with VE-822, a DNA repair inhibitor.* -
- The study utilized PDAC spheroid models and mouse models to analyze the combination's effects on tumor growth and the immune and fibrotic environment, revealing a strong synergistic effect and increased apoptosis.* -
- Results indicated that the FOLFIRINOX and VE-822 combo significantly inhibited tumor growth more than FOLFIRINOX alone, improved immune cell activity, and modified the tumor microenvironment, suggesting a potential strategy to enhance treatment effectiveness.*
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here, using the novel BiXAb™ tetravalent format platform, we generated bispecific antibodies against EGFR, HER2, or HER3 by considering rational epitope combinations.
View Article and Find Full Text PDFMonoclonal antibodies have revolutionized the treatment of many diseases, but their clinical efficacy remains limited in some other cases. Pre-clinical and clinical trials have shown that combinations of antibodies that bind to the same target (homo-combinations) or to different targets (hetero-combinations) to mimic the polyclonal humoral immune response improve their therapeutic effects in cancer. The approval of the trastuzumab/pertuzumab combination for breast cancer and then of the ipilimumab/nivolumab combination for melanoma opened the way to novel antibody combinations or oligoclonal antibody mixtures as more effective biologics for cancer management.
View Article and Find Full Text PDF